Erratum: The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value (Clinical Rheumatology (2007) vol. 26 10.1007/s10067-006-0389-9);The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value

Clinical Rheumatology

Volumn 26, Issue 5, 2007, Pages 723-728

  Ciferská, Hana ^a   Horák, Pavel ^a   Heřmanová, Zuzana ^b   Ordeltová, Marta ^b   Zadražil, Josef ^a   Tichý, Tomáš ^a   Ščudla, Vlastimil ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

Author keywords

Complement system; Disease activity; sCD30; sCD40L; Systemic lupus erythematodes

Indexed keywords

CD30 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C4;

ADULT; AGED; ARTICLE; BLOOD LEVEL; COMPLEMENT SYSTEM; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOLOGICAL PARAMETERS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 34147108301     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-007-0571-8     Document Type: Erratum

References (24)

1. Horak P, Scudla V, Hermanova Z et al (2001) Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus. Clin Rheum 20:337-344
2. Hermann M, Voll RE, Lolowos W et al (2000) Etiopathogenesis of systemic lupus erythematosus. Immunologist 8:345-350
3. Walport MJ (2002) Complement and systemic lupus erythematosus. Arthritis Res 4(Suppl 3):279-293
4. Falini B, Pileri S, Pizzolo G et al (1995) CD30(Ki-1) molecule a new cytokine receptor of the tumor necrosis factor receptor super family as a tool for the diagnosis and immunotherapy. Blood 85:1-14
5. Samy S, Bettina W, Richter M et al (2000) Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 96:4307-4312
6. Okamoto A, Yamamura M, Iwahashi M et al (2003) Pathophysiological functions of CD30+ CD4+ T cells in rheumatoid arthritis. Acta Med Okayama 57(6):267-277
7. Koshy M, Berger D, Crow MK (1996) Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98:826-837
8. Kimura K, Tsuda H, Kwangseok Y et al (2005) Study of plasma levels of soluble cd40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis. Ther Apher Dial 9(1):64-68
9. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
10. Bencivelli E, Vitali C, Isenberg DA et al and the European Consensus Study Group for Disease Activity in SLE (1992) Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheum 10:549-554
11. Bombardier C, Gladman DD, Urowitz MB et al and The Committee on Prognosis Studies in SLE (1992) Derivation of SLEDAI. Arthritis Rheum 35:630-640
12. Gladman DD, Urowitz MB, Gladman DD (1999) The SLICC/ACR Damage Index: progress report and experience in the field. Lupus 8:632-637
13. Cooper NR (1985) The classical complement pathway: Activation and regulation of first complement component. Adv Immunol 37:151-216
14. Elliot JA, Mathieson DR (1953) Complement in disseminated (systemic) lupus erythematosus. AMA Arch Derm Syphilol 68:119-128
15. Horak P, Hermanova Z, Ciferska H et al (2005) C1q complement and antibodies reflect SLE activity and kidney involvement. Clin Rheum 26:1-5
16. Trouw LA, Groeneveld TWL, Seelen MA et al (2004) Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 114:679-688
17. Hahn BH, Ebling F, Singh RR (2005) Cellular and molecular mechanisms of regulation of autoantibody production in lupus. Ann N Y Acad Sci 1051:433-441
18. Ramanujam M, Wang X, Huang W et al (2006) Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 116(3):724-734
19. Hill CM, Lunec J (1996) The TNF-ligand and receptor superfamilies: controllers of immunity and the Trojan horses of autoimmune disease? Mol Aspects Med 17(5):455-509
20. Caligaris-Cappio F, Bertero MT, Converso M et al (1995) Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheum 13(3):339-343
21. Kato K, Santana-Sahagun E, Rassentil LZ et al (1999) The soluble ligand CD40 sCD154 in systemic lupus erythematodes. J Clin Invest 104:947-955
22. Davis JC Jr, Totoritis MC, Rosenberg J et al (2001) Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 28(1):95-101
23. Goules A, Tzioufas AG, Manousakis MN et al (2006) Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J Autoimmun 26(3):165-171
24. Ho CY, Wong CK, Li EK et al (2003) Elevated plasma concentration of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematodes. Rheumatology (Oxford) 42:117-122